Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NYSE:MNK

Mallinckrodt (MNK) Stock Price, News & Analysis

Mallinckrodt logo

About Mallinckrodt Stock (NYSE:MNK)

Key Stats

Today's Range
$0.07
$0.13
50-Day Range
$0.14
$0.75
52-Week Range
$0.75
$6.42
Volume
39,227 shs
Average Volume
2.62 million shs
Market Capitalization
$1.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.

Receive MNK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mallinckrodt and its competitors with MarketBeat's FREE daily newsletter.

MNK Stock News Headlines

Mallinckrodt Completes Divestiture of Therakos® Business
Why I'm telling friends to avoid gold stocks
Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."
See More Headlines

MNK Stock Analysis - Frequently Asked Questions

Mallinckrodt plc (NYSE:MNK) released its quarterly earnings results on Tuesday, August, 4th. The company reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.55. The firm's revenue for the quarter was down 14.9% compared to the same quarter last year.
Read the conference call transcript
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mallinckrodt investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Micron Technology (MU), Endo International (ENDP), Bausch Health Companies (BHC), Meta Platforms (META) and Gerdau (GGB).

Company Calendar

Last Earnings
8/04/2020
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
2,700
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$47.48 per share

Miscellaneous

Free Float
13,131,000
Market Cap
$1.58 million
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NYSE:MNK) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners